VIENNA, Va., Aug. 7 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION
(Amex: CVM) will conduct two interviews on Tuesday, August 8, 2006. In the
interviews the CEO of CEL-SCI, Geert Kersten, will review current
operations and discuss the future prospects. The first interview will be
live on http://www.MN1.com at 11:30 a.m. eastern time. The second is a
phone interview with Wallst.net that can be accessed through their website
later that evening.
Interested parties may go to http://www.MN1.com to listen to
management's review of operations and discussion of future prospects. This
live broadcast is available to anyone at any computer connected to the
Internet. MN1.com is the only online destination that brings real microcap
news to investors and features live interaction with companies from the
AMEX, Bulletin Board, and Pink Sheets. Featuring Live Press Conferences,
All-Day Live Trading Commentary, Analyst Profiles, Interactive Forums, News
Items, and "The MicroBlog," MN1.com gives microcap investors the
information source necessary to trade in the markets. MN1.com boasts being
the largest true news company reporting on microcap traded stocks.
The CEL-SCI Corporation interview with Wallst.net is available at
http://www.wallst.net/. Wallst.net is owned and operated by WallStreet
Direct, Inc., a wholly owned subsidiary of Financial Media Group, Inc. The
website is a leading provider of financial news, media, tools and
community- driven applications for investors. Wallst.net offers visitors
free membership to its in-depth executive interviews, exclusive editorial
content, breaking news, and several proprietary applications.
CEL-SCI Corporation is developing new immune system based treatments
for cancer and infectious diseases. The Company has operations in Vienna,
Virginia and Baltimore, Maryland. The Company's lead product Multikine is
cleared to enter global Phase III clinical trials in advanced primary head
and neck cancer patients. CEL-SCI's other products, which are currently in
pre- clinical stage and are funded with U.S. government support, have shown
protection against a number of diseases in animal tests and are being
tested against diseases associated with bio-defense and avian flu.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
http://www.MN1.com http://www.wallst.net
CONTACT:
COMPANY: Gavin de Windt of CEL-SCI
Corporation, +1-703-506-9460; INVESTOR RELATIONS: Mike Lucci of
Lucci Financial Group, LLC, +1-248-723-3330, for CEL-SCI
Corporation
|
